Key Approvals (FDA, March 2026)
- Loargys (pegzilarginase-nbln): Treats hyperarginemia in adults and children with Arginase 1 Deficiency.
- Bysanti (milsaperidone): Approved for schizophrenia and bipolar I disorder.
- Adquey (difamilast): First-in-class topical therapy for mild to moderate atopic dermatitis.
Industry Trends
- Obesity & metabolic drugs (next-gen GLP-1 agonists) are expanding rapidly.
- Neurology & rare disease therapies dominate the pipeline, reflecting unmet patient needs.
- Oral alternatives to injectables are gaining traction, improving patient compliance.
Takeaway: 2026 is shaping up as a landmark year for first-in-class therapies that redefine treatment options across chronic and rare conditions.